Abstract:Immune checkpoint inhibitors are the most striking innovation in the clinical development of immunotherapy. Monoclonal antibodies (mAbs) restore and augment the antitumor immune activities of cytotoxic T cells by mainly blocking immune checkpoint molecules on T cells or their ligands on antigen-presenting and tumor cells. Based on preclinical data, many clinical trials have demonstrated the acceptable safety profiles and efficacies of mAb in various cancers. The A first-in-class approved immune checkpoint inhibitor is ipilimumab, which is a fully humanized mAb that blocks the immunosuppressive signal by cytotoxic T-lymphocyte antigen 4. In 2011, the US Food and Drug Administration approved the use of ipilimumab for the treatment of advanced metastatic melanoma. Then, nivolumab, which is a humanized mAb that blocks programmed death-1 (PD-1), was approved for use in the treatment of advanced melanoma in 2014 and of advanced non-small-cell lung carcinoma (NSCLC) in 2015 in Japan. Pembrolizumab, which is another anti-PD-1 antibody, was approved for use in the treatment of advanced melanoma and advanced NSCLC as the first-line therapy in 2016 in Japan. Thereafter, nivolumab was also approved for use in the treatment of advanced renal cell cancer in August 2016, of Hodgkin's lymphoma in December 2016, and of head and neck cancer in March 2017 in Japan. Moreover, phase III trials of anti-PD-1 mAb and anti-PD-ligand 1 mAb for use in the treatment of cancers, such as gastric, ovarian, bladder, and esophageal cancers, are ongoing. Several clinical trials have investigated new agents, alone and in combination, for use in the treatment of various cancers. Current advances in tumor immunology have unveiled the importance of immunosuppressive cells, such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, especially in a tumor microenvironment (TME). Some data from basic research in mouse models and the immunomonitoring of cancer patients suggest that the inhibition of immunosuppressive cells and the cytokines related to them activate and infiltrate cytotoxic T cells and in TME, which could be one of the next combination strategies. The current clinical development of, translational research on, and future challenges in utilizing immune checkpoint inhibitors are described.

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Tumor Immune Checkpoints and Their Associated Inhibitors

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

[Development of immune checkpoint inhibitors]

Therapeutic Development of Immune Checkpoint Inhibitors

Immune checkpoint: The novel target for antitumor therapy

[Immune-checkpoints: the new anti-cancer immunotherapies]

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Emerging immune checkpoint and its combination therapy in cancer treatment

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

PD-1/PD-L1 Blockade in Cancer Immunotherapy: Clinical Benefits, Limitations and Beyond

Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies

Immune Checkpoint Blockade and Its Combination Therapy with Small-Molecule Inhibitors for Cancer Treatment

Immune checkpoint signaling and cancer immunotherapy

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Immune Checkpoint Inhibitors' challenges, mechanisms and management

Small Molecule- and Peptide-Based Approaches